IPP Bureau
Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India
By IPP Bureau - November 17, 2023
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Alkem healthy lungs initiative to promote importance of inhalation therapy
By IPP Bureau - November 17, 2023
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric
By IPP Bureau - November 17, 2023
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Brenntag Specialties and Zeochem expand collaboration for Pharma EMEA
By IPP Bureau - November 17, 2023
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
By IPP Bureau - November 17, 2023
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
By IPP Bureau - November 16, 2023
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Sanofi completes closing for potential first-in-class vaccine against ExPEC
By IPP Bureau - November 16, 2023
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
By IPP Bureau - November 15, 2023
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
By IPP Bureau - November 15, 2023
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Kesin Pharma announces FDA approval and availability of Likmez oral suspension
By IPP Bureau - November 15, 2023
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
By IPP Bureau - November 15, 2023
Phase 3 data expected in the second half of 2024
Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr
By IPP Bureau - November 15, 2023
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
By IPP Bureau - November 15, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr
By IPP Bureau - November 15, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’
By IPP Bureau - November 14, 2023
Yesafili, received marketing authorization approval from the European Commission for the European Union
